Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American brain tumor consortium report

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2188-2194

  Chang, Susan M ^a   Kuhn, John G ^a   Rizzo, Jinee ^a   Robins, H Ian ^a   Schold Jr , S Clifford ^a   Spence, Alexander M ^a   Berger, Mitchel S ^a   Mehta, Minesh P ^a   Bozik, Michael E ^a   Pollack, Ian ^a   Gilbert, Mark ^a   Fulton, Dorcas ^a   Rankin, Cathryn ^a   Malec, Mary ^a   Prados, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG CLEARANCE; FEMALE; GLIOBLASTOMA; HUMAN; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 0031801368     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2188     Document Type: Article

References (43)

1. Rowinsky EK, Cazenave LA, Donehower RC: Paclitaxel: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259, 1990
2. McGuire WP, Rowinsky EK, Rosenhein NB, et al: Paclitaxel: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
3. Spencer CM, Faulds D: Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48:794-847, 1994
4. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 15:1004-1014, 1995
5. Millward MJ, Bishop JF, Friedlander M, et al: Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 14:142-148, 1996
6. Wilson WH, Chabner BA, Bryant G, et al: Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 13:381-386, 1995
7. Horwitz SB: Paclitaxel: Mechanisms of action. Ann Oncol 5:S3-S6, 1994 (suppl 6)
8. Younes A, Sarris A, Melnyk A, et al: Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 13:583-587, 1995
9. Schiller JH, Storer B, Tutsch K, et al: Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248, 1994
10. Klecker RW, Jamis-Dow CA, Egorin MJ, et al: Distribution and metabolism of 3H-taxol in the rat. Proc Am Assoc Cancer Res 34:381, 1993 (abstr)
11. 3H-paclitaxel in rats: A quantitative autoradiographic study. Cancer Chemother Pharmacol 37: 173-178, 1995
12. 1 mice. Cancer Chemother Pharmacol 34:465-471, 1994
13. Rowinsky EK, Burke PJ, Karp JE, et al: Phase I and pharmacodynamic study of paclitaxel in refractory acute leukemias. Cancer Res 49:4640-4647, 1989
14. Lesser GJ, Grossman SA, Eller S, et al: 3H-Paclitaxel (3H-P) tissue concentrations within intracranial malignant gliomas and normal rat brains after intravenous administration. Proc Am Soc Clin Oncol 14:149, 1995 (abstr 292)
15. Heimans JJ, Vermorken JB, Wolbers JG, et al: Paclitaxel concentrations in brain tumor tissue. Ann Oncol 5:951-953, 1994
16. Cahan MA, Walter KA, Colvin OM, et al: The cytotoxicity of paclitaxel in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33:441-444, 1994
17. Riondel J, Jacrot M, Fessi M, et al: Effects of free and liposome-encapsulated paclitaxel on two brain tumors xenografted into nude mice. In Vivo 6:23-27, 1992
18. Riondel J, Jacrot M, Picot F, et al: Therapeutic response to paclitaxel of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol 17:137-142, 1986
19. Chamberlain MC, Kormanik P: Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13:2066-2071, 1995
20. Prados MD, Schold SC, Spence AM, et al: Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14:2316-2321, 1996
21. Gatzemeier U, Neuhauss R, Schluter I, et al: Single agent paclitaxel as a 3 hour infusion. Semin Oncol 23:94-97, 1996 (suppl 16)
22. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusions. J Clin Oncol 12:2654-2666, 1994
23. Rowinsky EK, Wright M, Monsarrat B, et al: Clinical pharmacology and metabolism of paclitaxel: Update 1993. Ann Oncol 5:S7-S16, 1994 (suppl 6)
24. Cresteil T, Monsarrat B, Alvinerie P, et al: Taxol metabolism by human liver microsomes: Identification of cytochrome P-450 isozymes involved in its biotransformation. Cancer Research 54:386-392, 1994
25. Huizing MT, Keung AC, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in palitnum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
26. Huizing MT, Vermorken JB, Rosing WW, et al: Pharmacology of paclitaxel and three main metabolites in patients with advanced breast cancer refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Center (ECC) trial. Proc Am Soc Clin Oncol 14:460, 1995 (abstr 1482)
27. 2 receptor antagonists that differ in P450 modulation activity: Comparative effects on paclitaxel clearance rates and neutropenia. Can Chemo Pharm 36:227-232, 1995
28. Sonnichsen DS, Relling MV: Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27:256-269, 1994
29. Fetell MR, Grossman SA, Fisher JD, et al: Preirradadiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology and drug interactions. J Clin Oncol 15:3121-3128, 1997
30. Postma TJ, Vermorken JB, Liefting AJ, et al: Paclitaxel-induced neuropathy. Ann Oncol 6:489-494, 1995
31. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al : Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993 (suppl 3)
32. Mc Guire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
33. Brown T, Havlin K, Weiss G, et al: A phase I trial of Taxol given by a 6-hour infusion. J Clin Oncol 9:1261-1267, 1991
34. Hurwitz CA, Relling MV, Weitman SD, et al: Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncoi 11:2324-2329, 1993
35. Perry JR, Warner EW: Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 46:1596-1599, 1996
36. Stemmer SM, Cagnoni PJ, Shpall EJ, et al: High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progeniote-cell support: A phase I trial. J Clin Oncol 14:1463-1472, 1996
37. Cagnoni PJ, Shpall EJ, Bearman SI, et al: Paclitaxel-containing high-dose chemotherapy: The University of Colorado experience. Semin Oncol 23:43-48, 1996 (suppl 15)
38. Webster LK, Crinis NA, Morton CG, et al: Plasma alcohol concentrations in patients following paclitaxel infusion. Can Chemo Pharmacol 37: 499-501, 1996
39. Rischin D, Webster LK, Millward MJ, et al: Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24 hour infusions of paclitaxel. J Natl Cancer Inst 88:1297-1301, 1996
40. Webster L, Linsenmeyer M, Millward M, et al: Measurement of cremophor EL following Taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistance phenotype. J Natl Cancer Inst 85:1685-1690, 1993
41. Woodcock DM, Jefferson S, Linsenmeyer ME, et al: Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50:4199-4203, 1990
42. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995
43. Jette L, Gerard FM, Leclerc JM, et al: Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol 50:1701-1709, 1995